Plasma Glial Fibrillary Acid Protein and Phosphorated Tau 181 Association with Presynaptic Density-Dependent Tau Pathology at <sup>18</sup>F-SynVesT-1 Brain PET Imaging.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 39560478.
- Also identified by DOI 10.1148/radiol.233019 and PMC identifier 11605102.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Background Synaptic loss is an important factor in Alzheimer disease (AD); however, blood assays that conveniently and rapidly reflect changes in synaptic density are lacking. Purpose To correlate multiple potential synaptic blood markers with synaptic density measured using <sup>18</sup>F-SynVesT-1, a fluorine 18 (<sup>18</sup>F)-labeled radiotracer, brain PET and to explore the independent associations between these markers and synaptic density. Materials and Methods This prospective study included 50 cognitively unimpaired (mean age, 65.0 years ± 8.3 [SD]; 37 female) participants and 70 participants with cognitive impairment (mean age, 69.5 years ± 7.9; 43 female) from the Memory Clinic of Shanghai Jiao Tong University Affiliated Ruijin Hospital and communities in Shanghai. Amyloid-β (Aβ) and tau were assessed using <sup>18</sup>F-florbetapir and <sup>18</sup>F-MK6240 PET/CT. Synaptic density was evaluated with <sup>18</sup>F-SynVesT-1 PET/MRI. Pearson correlation analysis was used to investigate relationships of plasma (Aβ42/40 ratio, phosphorylated tau 181 [p-tau-181], glial fibrillary acid protein [GFAP], neurofilament light) and serum (C-reactive protein, tumor necrosis factor-α, α-synuclein, neurogranin, active plasminogen activator inhibitor-1, tissue plasminogen activator) biomarkers with synaptic density. Linear regression models and mediation analysis were used to explore effects of other AD-related pathologies on these relationships. Results Correlations were observed between increased p-tau-181 and GFAP and decreased synaptic density in global cortex (<i>r</i><sub>p-tau-181</sub> = -0.352, <i>r</i><sub>GFAP</sub> = -0.386; both <i>P</i> < .001) and hippocampus (<i>r</i><sub>p-tau-181</sub> = -0.361, <i>r</i><sub>GFAP</sub> = -0.369; both <i>P</i> < .001) at <sup>18</sup>F-SynVesT-1 PET/MRI. The relationships between p-tau-181 and GFAP with <sup>18</sup>F-SynVesT-1 PET/MRI persisted after controlling for plasma Aβ42/40 ratio, Aβ PET, or cortical thickness (<i>P</i> value range, <.001-.01). This association disappeared after controlling for tau PET (<i>P</i> value range, .08-.83). Conclusion Plasma p-tau-181 and GFAP are closely associated with synaptic density measured using <sup>18</sup>F-SynVesT-1 PET/MRI, with the relationship primarily influenced by tau accumulation rather than Aβ deposition or cortical thickness. © RSNA, 2024 <i>Supplemental material is available for this article.</i> See also the editorial by Giannakopoulos in this issue.
Medical subject headings
- tau Proteins
- Glial Fibrillary Acidic Protein
- Brain